Efficacy and Safety Study of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
A Phase 3, Randomized, Double-blind, Double-dummy, Multicenter, Prospective Study to Assess the Efficacy and Safety of Eravacycline Compared With Levofloxacin in Complicated Urinary Tract Infections
Sponsor: Tetraphase Pharmaceuticals, Inc
This PHASE3 trial investigates cUTI and is currently completed. Tetraphase Pharmaceuticals, Inc leads this study, which shows 10 recorded versions since 2014 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Feb 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Feb 2022 [monthly]
Completed PHASE3
▶ Show 5 earlier versions
-
May 2019 — Jan 2021 [monthly]
Completed PHASE3
-
Jan 2019 — May 2019 [monthly]
Completed PHASE3
Status: Unknown Status → Completed
-
Jun 2018 — Jan 2019 [monthly]
Unknown Status PHASE3
Status: Active Not Recruiting → Unknown Status
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Oct 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Tetraphase Pharmaceuticals, Inc
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Armenia, Colombia , Baja, Hungary , Barranquilla, Colombia , Benoni, South Africa , Brasov, Romania , Brno, Czechia , Bucharest, Romania , Budapest, Hungary , Castellanza, Italy , Chernivtsi, Ukraine and 67 more locations